The Value of Early Site Selection in Type 2 Diabetes Trials, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss protocols to refine inclusion/exclusion criteria and methods to utilize/analyze investigator performance in type 2 diabetes trials. Attendees will learn about real-world data analysis and its role in site selection as well as the methodology of site list development.

This webinar will discuss Covance’s well-refined internal process of site selection, and lessons learned that would benefit their industry partners in site selection.

At Covance, they know that time is of the essence across their diabetes trials. Developing these trials in the most cost-efficient manner makes upfront planning crucial, but interrogating the best data resources to augment team expertise is a difficult task. Covance understands that delays to the development of a well-defined site list are costly, and that selection of the wrong investigators could cost a company crucial time to market. They use a variety of data sources to guide early site selection, honing in on the best possible sites and countries upfront to pre-identify the most effective sites for a trial. Their extensive data repositories allow them to create a master site list without the need for long, overly time-consuming feasibility questionnaires.

This webinar will discuss Covance’s well-refined internal process of site selection, and lessons learned that would benefit their industry partners in site selection. Panelists will discuss using comprehensive protocol or concept analysis of internally available studies to identify similar trials, how to incorporate sites from investigator performance databases driven by trial expertise, using data to hone in on specific patient locations, and using all of this to develop strong site lists to save time and money in early study planning and site selection.

Join expert speakers from Covance, Kevin Melvin, Executive Director, Operational Strategy & Planning, Cardiovascular, Metabolic, Endocrine and Renal; Earl Seltzer, Sr. Director, Feasibility and Site Selection; and J.B. Flinders, MPH, MBA, Sr. Director, Operational Strategy & Planning in a live webinar on Thursday, December 3, 2020 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit The Value of Early Site Selection in Type 2 Diabetes Trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website